Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.67 |
| ▸ | TNKS | O95271 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obovator SCHEMBL33525039 | 1.00 | MMP2 (0.67) | MMP2TNKSPARP1TNKS2XDH | |
| SCHEMBL18838060 | 0.88 | TNKS (0.61) | MMP2TNKSTNKS2ALDH1A1ALOX5 | |
| SCHEMBL30114989 | 0.87 | TNKS (0.69) | MMP2TNKSPARP1TNKS2XDH | |
| Isomagnolol SCHEMBL30069180 | 0.87 | ALDH1A1 (0.66) | MMP2TNKSPARP1TNKS2XDH | |
| SCHEMBL4457177 | 0.83 | ALDH1A1 (0.61) | MMP2TNKSPARP1TNKS2XDH | |
| Obovatal SCHEMBL3383286 | 0.81 | MMP2 (1.00) | MMP2TNKSPARP1TNKS2XDH | |
| SCHEMBL9352993 | 0.78 | ALDH1A1 (0.68) | MMP2TNKSPARP1XDHALDH1A1 | |
| SCHEMBL88416 | 0.78 | ALDH1A1 (0.68) | MMP2TNKSPARP1XDHALDH1A1 | |
| SCHEMBL2493537 | 0.78 | TNKS (0.63) | MMP2TNKSPARP1TNKS2XDH | |
| SCHEMBL10321982 | 0.78 | TNKS (0.52) | MMP2TNKSPARP1TNKS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | KULKARNI ASHISH (US) | 2026-04-02 | — | — | US | claimed |
| EP-4660255-A1 | WATER PIGMENT PASTE, WATER PIGMENT PASTE, WATER COATING SYSTEM | DAW SE (DE) | 2025-12-10 | — | — | EP | claimed |
| US-20240382451-A1 | ORGANONITRO AND SULFOXYALKYL ORGANONITRO COMPOUNDS FOR USE IN TREATING MEDICAL DISORDERS | EPICENTRX INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4355320-A1 | ORGANONITRO AND SULFOXYALKYL ORGANONITRO COMPOUNDS FOR USE IN TREATING MEDICAL DISORDERS | EpicentRx, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| CN-115792021-A | Method for analyzing different chemical components of combined decoction and single decoction of Dachengqi decoction by using UPLC-Q-TOF-MS/MS (ultra performance liquid chromatography-quadrupole-time of flight-mass spectrometry) | 广东省第二中医院（广东省中医药工程技术研究院） | 2023-03-14 | — | — | CN | claimed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | claimed |
| US-20090311354-A1 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF MAGNOLIA OBOVATA THUNB FOR TREATING AND PREVENTING INFLAMMATION DISEASE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-17 | — | — | US | claimed |
| US-20090263521-A1 | COMPOSITION FOR THE TREATMENT OF CANCERS AND INHIBITION OF METASTASIS CONTAINING EXTRACTS OR FRACTIONS OF THE MAGNOLIA OBOVATA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-10-22 | — | — | US | claimed |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-09-24 | — | — | US | claimed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | claimed |
| US-20080194702-A1 | Obovatol Having Anti-Anxiety Activity | HONG, JIN TAE (KR) | 2008-08-14 | — | — | US | claimed |
| WO-2008072855-A1 | PHARMACEUTICAL COMPOSITION FOR OBOVATOL FOR THE PREVENTION AND TREATMENT OF RESTENOSIS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-06-19 | — | — | WO | claimed |
| US-20080139668-A1 | PHARMACEUTICAL COMPOSITION FOR OBOVATOL FOR THE PREVENTION AND TREATMENT OF RESTENOSIS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-06-12 | — | — | US | claimed |
| US-20070185215-A1 | Pharmaceutical composition containing obovatol as an active ingredient for the prevention and treatment of neurodegenerative diseases | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-08-09 | — | — | US | claimed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | claimed |
| WO-2006121258-A1 | COMPOSITION COMPRISING AN OBOVATOL HAVING ANTI-ANXIETY ACTIVITY | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | MMP2, MMP9, MMP7 | MMP2 1/4885TNKS 3119/4885PARP1 1800/4885 |
| US-20080194702-A1 | Obovatol Having Anti-Anxiety Activity | OCIAD2, OCIAD1, CUL4B | MMP2 207/4885TNKS 4776/4885PARP1 4696/4885 |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | MMP2 2582/4885TNKS 860/4885PARP1 1179/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | MMP2 80/4885TNKS 3186/4885PARP1 3199/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | MMP2 3235/4885TNKS 825/4885PARP1 163/4885 |
| US-20080139668-A1 | PHARMACEUTICAL COMPOSITION FOR OBOVATOL FOR THE PREVENTION AND TREATMENT OF RESTENOSIS | APOB, OSTC, LIPG | MMP2 173/4885TNKS 3642/4885PARP1 2616/4885 |
| US-20090311354-A1 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF MAGNOLIA OBOVATA THUNB FOR TREATING AND PREVENTING INFLAMMATION DISEASE | NOS3, NOS2, TNF | MMP2 2055/4885TNKS 4649/4885PARP1 4425/4885 |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | MMP2, MMP9, MMP7 | MMP2 1/4885TNKS 3119/4885PARP1 1800/4885 |
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | NLRP3, NLRP1, IL1B | MMP2 1244/4885TNKS 2076/4885PARP1 2528/4885 |
| US-20090239955-A1 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient | OGFRL1, TP53, BAX | MMP2 640/4885TNKS 4461/4885PARP1 4591/4885 |
| US-20070185215-A1 | Pharmaceutical composition containing obovatol as an active ingredient for the prevention and treatment of neurodegenerative diseases | ACHE, NOS1, NOS3 | MMP2 732/4885TNKS 3747/4885PARP1 3946/4885 |
| US-20240382451-A1 | ORGANONITRO AND SULFOXYALKYL ORGANONITRO COMPOUNDS FOR USE IN TREATING MEDICAL DISORDERS | PMP22, AS3MT, MPST | MMP2 3896/4885TNKS 3462/4885PARP1 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.